CJC 1295 (No DAC)

Overview

Physiological stimulation of the GH axis via GHRH signaling.

Mechanism of action

CJC 1295 No DAC is commonly used to refer to Modified GRF (1 to 29), a 29 amino acid analogue of GHRH (growth hormone releasing hormone). In research contexts it is discussed as a shorter acting GHRH analogue intended to stimulate endogenous pulsatile growth hormone release through the GHRH receptor on pituitary somatotroph cells.

The No DAC designation indicates the compound does not include the Drug Affinity Complex used in CJC 1295 with DAC, a modification designed to bind albumin and extend half life. This distinction matters because the prolonged GH and IGF 1 stimulation reported for CJC 1295 with DAC is tied to albumin binding, not to the core GHRH fragment alone.

GHRH analogues were engineered to improve stability by resisting rapid enzymatic breakdown, including N terminal cleavage mechanisms that can inactivate native fragments quickly. As with all GH axis modulators, responsible communication should stay within studied and investigated language and avoid implying approved medical use where it does not exist.

• Modified GRF (1 to 29), No DAC refers to a stabilized GHRH fragment concept.
• CJC 1295 with DAC refers to an albumin binding long acting research design.

Authenticity

To validate your product, scan the QR code on the packaging or open the verification page for this product group.